Tillkännagivande • Jun 19
Apontis Pharma AG, Annual General Meeting, Jul 29, 2025 Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time. Tillkännagivande • Nov 21
Shares of Apontis Pharma to Delist Following the Tender Offer Zentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said. Price Target Changed • Nov 15
Price target decreased by 9.4% to €15.75 Down from €17.38, the current price target is an average from 4 analysts. New target price is 66% above last closing price of €9.46. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year. Tillkännagivande • Oct 24
Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH). Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025. Reported Earnings • Aug 14
First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023) First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. New Risk • Aug 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€62.1m market cap, or US$67.8m). Price Target Changed • Apr 15
Price target increased by 15% to €17.50 Up from €15.17, the current price target is an average from 3 analysts. New target price is 104% above last closing price of €8.56. Stock is down 21% over the past year. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year. Price Target Changed • Apr 12
Price target increased by 10% to €16.17 Up from €14.67, the current price target is an average from 3 analysts. New target price is 112% above last closing price of €7.64. Stock is down 30% over the past year. The company is forecast to post earnings per share of €0.13 next year compared to a net loss per share of €1.36 last year. Reported Earnings • Mar 28
Full year 2023 earnings released Full year 2023 results: Revenue: €38.7m (down 31% from FY 2022). Net loss: €11.3m (down €14.0m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Price Target Changed • Nov 10
Price target decreased by 15% to €16.13 Down from €19.00, the current price target is an average from 3 analysts. New target price is 398% above last closing price of €3.24. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €1.08 compared to earnings per share of €0.32 last year. Tillkännagivande • Nov 09
Apontis Pharma Provides Earnings Guidance for the Full Year 2023 Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorates as stock falls 31% After last week's 31% share price decline to €5.42, the stock trades at a trailing P/E ratio of 17.7x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 55% over the past year. Tillkännagivande • Jul 29
Apontis Pharma AG to Report First Half, 2023 Results on Aug 10, 2023 Apontis Pharma AG announced that they will report first half, 2023 results on Aug 10, 2023 Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €8.68, the stock trades at a trailing P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 25% over the past year. Tillkännagivande • Jun 29
Aontis Pharma AG Launches Single Pill Finder and Distribution of Single Pill Rosazimib APONTIS PHARMA AG launched Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023. Single Pill Finder online application shows real-time options to simplify therapy. Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill. New Single Pill Rosazimib on the market. Further Single Pills to be marketed in 2023. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills. As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loose combination preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the portion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto " by physicians for physicians". Launch of new Single Pill RosazIMib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primaryhypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome. Price Target Changed • May 05
Price target decreased by 9.4% to €25.67 Down from €28.33, the current price target is an average from 3 analysts. New target price is 285% above last closing price of €6.66. Stock is down 55% over the past year. The company is forecast to post earnings per share of €0.07 for next year compared to €0.32 last year. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorates as stock falls 36% After last week's 36% share price decline to €7.00, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past year. Reported Earnings • Apr 02
Full year 2022 earnings released Full year 2022 results: Revenue: €58.4m (up 14% from FY 2021). Net income: €2.69m (up €3.43m from FY 2021). Profit margin: 4.6% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €9.86, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 24% over the past year. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €9.04, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 42% over the past year. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 21% share price gain to €7.72, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 65% over the past year. Reported Earnings • Apr 02
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.088 loss per share (up from €0.18 loss in FY 2020). Revenue: €51.2m (up 30% from FY 2020). Net loss: €745.2k (loss narrowed 37% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 9.0%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. 
